Cellectar Biosciences (CLRB) reported a net loss of $6.9 million, or $0.57 per basic and diluted share, for the quarter ended June 30, 2026. The company had $34.0 million in cash and cash equivalents at quarter-end.
The company initiated site activation for its confirmatory Phase 3 trial of iopofosine I 131 in relapsed or refractory Waldenstrom macroglobulinemia and plans to submit a New Drug Application in mid-2027 under the FDA's Accelerated Approval Program.
- Second-quarter research and development expense was $4.6 million, compared with $2.4 million a year earlier.
- General and administrative expense was $2.6 million, compared with $3.6 million in the prior-year period.
- Cellectar initiated enrollment and dosed the first patients in its Phase 1b trial of CLR 125 in refractory triple-negative breast cancer.
- In the CLOVER WaM study subset of 24 evaluable patients immediately following BTK inhibitor therapy, iopofosine I 131 reported a 79.2% major response rate and 87.5% overall response rate.
- The company said its June 30 cash balance is adequate to fund budgeted operations into the second quarter of 2027.
$CLRB Hedge Fund Activity
We have seen 6 institutional investors add shares of $CLRB stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- EMPERY ASSET MANAGEMENT, LP added 189,605 shares (+inf%) to their portfolio in Q2 2026, for an estimated $527,101
- PERSISTENT ASSET PARTNERS LTD added 92,983 shares (+inf%) to their portfolio in Q2 2026, for an estimated $258,492
- DRW SECURITIES, LLC removed 45,190 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $114,782
- WARBERG ASSET MANAGEMENT LLC removed 13,900 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $38,642
- XTX TOPCO LTD removed 12,243 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $31,097
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 12,204 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $30,998
- UBS GROUP AG added 7,049 shares (+271.3%) to their portfolio in Q1 2026, for an estimated $17,904
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
